A Multicenter, Open-Label Phase 1/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Efficacy of BR790 Tablets in Combination With Tislelizumab Injection in Patients With Advanced Solid Tumors
Latest Information Update: 22 Aug 2022
At a glance
- Drugs BR 790 (Primary) ; Tislelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Gopherwood Biotech
Most Recent Events
- 22 Aug 2022 New trial record